Biogen has selected Cognizant's SmartTrials platform to aggregate and store clinical trial operational and patient data. Cambridge, Mass.-based Biogen has a portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of neurology research, working to develop novel therapies for conditions with few or no treatment options.

The SmartTrials platform provides real-time risk assessment and global clinical trial oversight to help companies reduce risk and improve collaboration, quality and compliance. It delivers actionable outcomes for faster data-driven decisions, transforming clinical operations into a more agile, innovative and efficient process. The SmartTrials platform allows biopharma companies to support clinical operations by standardizing data exchange, and replacing several data repositories with a centralized information hub.

"We are excited to partner with leading biopharma companies to drive innovation in clinical development," said Bhaskar Sambasivan, vice president of life sciences practice at Cognizant. "The SmartTrials platform makes it easier for users and decision makers to more effectively monitor clinical trial progress, reduce risk and costs, with the goal of bringing new therapies to market faster."